As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
20 Analysts have issued a NewAmsterdam Pharma Company forecast:
20 Analysts have issued a NewAmsterdam Pharma Company forecast:
Jun '23 |
+/-
%
|
||
Revenue | 107 107 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -147 -147 |
-
|
EBIT (Operating Income) EBIT | -147 -147 |
4,550%
4,550%
|
Net Profit | -158 -158 |
5,603%
5,603%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 68 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
Head office | Netherlands |
Employees | 77 |
Website | ir.newamsterdampharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.